Alkermes plc.
corporate_fare Company Profile
Alkermes plc. (NASDAQ:ALKS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ALKS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-21, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ALKS spans 8-K/A, 10-Q, 8-K, DEF 14A.
Recent high-impact activity:
- Alkermes' ALKS 7290 Shows Clinically Meaningful ADHD Symptom Improvement in Phase 1b
- Alkermes Details $8M Equity Package for Incoming CEO Blair Jackson, Adds President Title and Board Seat
- Alkermes Q2 Revenue Jumps 27% to $496M, Medicaid Rebate Shifts in Focus
- LUMRYZ Drives 27% Revenue Surge for Alkermes, but Acquisition Costs and Debt Push Q2 Profit to Near Breakeven
- Alkermes Reports Strong Q2 Revenue, Widens Full-Year GAAP Net Loss Guidance, and Announces CEO Transition
Financial Snapshot
Short Interest & Short Volume
10.70 days to coverFINRA reported short interest of 15,156,775 shares in ALKS as of the September 15, 2026 settlement, a 3.0% increase from the prior period — about 10.7 days to cover at its recent average daily volume. On October 2, 2026, 56.8% of ALKS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.